Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study
Pharmaceutical company, Qnovia has shared positive results from initial clinical trials of its prescription inhaled smoking cessation therapy.
The drug delivery platform, QN-01, is under evaluation in the US through the US Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) while the Medicines and Healthcare Products Regulatory Agency (MHRA) reviews it in the UK.
Despite healthcare efforts to educate the public on the dangers of smoking tobacco is responsible for approximately 480,000 deaths each year in the US and can cause numerous health conditions such as cancer, heart disease and strokes. According to the World Health Organization (WHO) one in three of the world’s cigarettes is smoked in China, where lung cancer is epidemic.
Qnovia claim QN-01 has the potential to fill the void for more effective pharmacotherapies and nicotine replacement therapies (NRTs). Traditional treatments miss the mark and fail to deliver nicotine rapidly during peak levels which is crucial when trying to alleviate withdrawal symptoms.
Results posted from the trial showed that QN-01 had an “exceptional” pharmacokinetic profile compared to existing NRTs. The data of this study has been filed with the FDA for the upcoming Investigational New Drug (IND) submission, and if approved it could help smokers quit with inhalable nicotine replacement therapies.
Mario Danek, Chief Technology Officer of Qnovia, said: “This data demonstrates our device has significant potential in bringing new hope to smokers who want to quit smoking.” He affirmed the company’s commitment to advancing QN-01 into the next stage of clinical development, working closely with regulatory agencies to make this treatment option accessible to millions of smokers striving to quit.”
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Brian Quigley, CEO of Qnovia, added: “We believe our nicotine delivery platform could be a game-changer in alleviating cravings and withdrawal symptoms for those smokers who need it most.”
In May 2023 the company raised $2.87 million of a planned $5 million equity financing round.
Source link
#Qnovias #inhaledsmokingcessationtherapy #triumphs #clinical #study
